December 18, 2020
ARLINGTON, Va. — HDA President and CEO Chester “Chip” Davis, Jr., released a statement following the U.S. Food and Drug Administration’s (FDA) granting of an Emergency Use Authorization for the Moderna COVID-19 vaccine candidate.
“Today marks another significant step in our nation’s response to COVID-19 that will allow for more Americans to receive a vaccine in the coming months under the direction of the Centers for Disease Control and Prevention (CDC), states and public health experts. HDA appreciates the tireless work of our manufacturer trading partners, FDA, CDC and Operation Warp Speed to advance two vaccine candidates so quickly.
“Each part of the healthcare system — in close coordination with federal and state governments — has a role to play in this massive logistics undertaking. HDA is pleased that the federal government has recognized and is relying on the expertise of our healthcare distributor members in ensuring vaccines, the essential supplies needed to administer them, and other COVID-19 related treatments and therapeutics are delivered safely and efficiently to provider points of administration. This spirit of public- and private-sector collaboration will not only be important in bringing an end to the COVID-19 pandemic, but also enhancing our resiliency for future public health crises.”
The Healthcare Distribution Alliance (HDA) represents primary pharmaceutical distributors — the vital link between the nation’s pharmaceutical manufacturers and pharmacies, hospitals, long-term care facilities, clinics and others nationwide. Since 1876, HDA has helped members navigate regulations and innovations to get the right medicines to the right patients at the right time, safely and efficiently. The HDA Research Foundation, HDA’s non-profit charitable foundation, serves the healthcare industry by providing research and education focused on priority healthcare supply chain issues.